Impact of Body Mass Index on Short-Term Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Newfoundland and Labrador, Canada

Table 6

Multivariate adjusted OR for nonvascular in-lab complications in patients undergoing PCI.

	OR	95% CI	value
Age	1.02	1.001–1.03	0.039
Male	0.64	0.47–0.87	0.005
GI/liver disease	1.53	1.02–2.27	0.038
GP IIb/IIIa inhibitors in-lab	4.99	3.65–6.81	0.000
IV heparin in-lab	1.70	1.14–2.52	0.009
Coumadin	2.38	1.14–4.98	0.021
Closure device	0.28	0.19–0.40	0.000
BMI (referent category is normal weight)
Overweight	0.93	0.62–1.38	0.705
Obese	0.54	0.58–1.32	0.879

Adjusted for age, BMI, closure device, coumadin, diabetes, DVT, family history of premature CAD, GP IIb/IIIa inhibitors in-lab, gender, GI/liver disease, hypertension, IV heparin in-lab, LMWH in-lab, prior CABG, prior COPD, prior CVD, prior HF, prior PCI, prior PVD, pulmonary embolism, sheath size, and year.
BMI: body mass index; CAD: coronary artery disease; CABG: coronary artery bypass grafting; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; DVT: deep vein thrombosis; GP: glycoprotein; HF: heart failure; LMWH: low molecular weight heparin; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease.